Phase 2 Liver Cancer Trial, Recruiting NCT06904196 Sponsor: Second Affiliated Hospital of Guangzhou Medical University Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT06904196
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC), either confirmed by a tissue sample or by clinical assessment
  • Your liver cancer has stopped responding to a procedure called TACE (a treatment that delivers medicine directly to liver tumours through blood vessels), based on specific medical guidelines
  • You are allowed to join if your liver cancer came back after surgery or a tumour-destroying procedure (such as ablation)
  • You have at least one liver tumour that can be measured on scans
  • Your liver is functioning at an acceptable level (Child-Pugh class A or B — confirm with trial site)
  • You are generally well enough to carry out light daily activities (confirm with trial site)
  • Your tumours take up less than 70% of your liver
  • You have been assessed and confirmed as suitable for a treatment called SIRT (a type of internal radiation therapy), including a specific scan to check blood flow in your liver
  • Your blood counts, liver function, kidney function, and other key body measurements meet the required levels (confirm with trial site for specific numbers)
  • Doctors expect you to live for at least 3 more months

Who may not be able to join:

  • Your cancer has spread to parts of the body outside the liver
  • A blood clot from the tumour is blocking the main blood vessel supplying your liver (the main portal vein or both of its main branches)
  • Your cancer has grown into the large vein that carries blood to the heart (the vena cava)
  • You have previously received certain liver-directed chemotherapy (HAIC), radiotherapy, or systemic (whole-body) drug treatments for your liver cancer
  • You have had an organ or cell transplant in the past
  • You have a history of bleeding from swollen veins in your oesophagus (food pipe) or stomach
  • You have a history of a condition called hepatic encephalopathy (where the liver cannot properly remove toxins, affecting brain function)
  • You have been diagnosed with another type of cancer (other than liver cancer)
  • You are living with HIV infection

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mingyue Cai, Dr., Second Affiliated Hospital of Guangzhou Medical University

Phone: +86-20-34156205

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
31 March 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective response rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov